Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $44.00 Average Price Target from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $43.80.

A number of equities research analysts have weighed in on INO shares. Oppenheimer cut their price objective on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, August 12th. Royal Bank of Canada cut their price objective on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating on the stock in a report on Friday. Finally, HC Wainwright restated a “neutral” rating and issued a $15.00 price objective on shares of Inovio Pharmaceuticals in a report on Monday, July 15th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at approximately $71,000. The Manufacturers Life Insurance Company purchased a new stake in Inovio Pharmaceuticals in the second quarter worth approximately $82,000. Dimensional Fund Advisors LP purchased a new stake in Inovio Pharmaceuticals in the second quarter worth approximately $605,000. Cornercap Investment Counsel Inc. purchased a new stake in Inovio Pharmaceuticals in the second quarter worth approximately $184,000. Finally, American Century Companies Inc. boosted its holdings in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 12,100 shares during the last quarter. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $5.55 on Friday. Inovio Pharmaceuticals has a 1 year low of $3.89 and a 1 year high of $14.75. The company’s 50-day moving average is $7.30 and its 200 day moving average is $9.43. The stock has a market capitalization of $143.81 million, a P/E ratio of -1.51 and a beta of 0.82.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.10 million. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 99.51%. During the same quarter in the prior year, the firm earned ($1.56) EPS. Research analysts anticipate that Inovio Pharmaceuticals will post -4.64 earnings per share for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.